Zoetis (NYSE:ZTS) Updates FY 2025 Earnings Guidance

Zoetis (NYSE:ZTS) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 6.000-6.100 for the period, compared to the consensus earnings per share estimate of 6.300. The company issued revenue guidance of $9.2 billion-$9.4 billion, compared to the consensus revenue estimate of $9.6 billion.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Morgan Stanley reduced their price objective on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. UBS Group assumed coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Stifel Nicolaus cut their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $214.00.

Zoetis Stock Down 5.6 %

ZTS traded down $9.67 on Thursday, hitting $164.21. The company had a trading volume of 9,087,352 shares, compared to its average volume of 2,842,682. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis has a 52-week low of $144.80 and a 52-week high of $200.53. The stock has a fifty day simple moving average of $169.08 and a 200-day simple moving average of $179.08. The firm has a market capitalization of $74.09 billion, a P/E ratio of 30.90, a P/E/G ratio of 2.77 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. As a group, equities analysts expect that Zoetis will post 5.9 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.22%. Zoetis’s payout ratio is 37.59%.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.